100 results
8-K
EX-99.1
SAVA
Cassava Sciences Inc
28 Feb 24
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
9:22am
of an open-label extension study for our Phase 3 program. This study is designed to provide no-cost access to oral simufilam for up to one year … Herrington & Sutcliffe LLP to investigate these allegations. The investigation had access to Company personnel, communications, documents, data
8-K
EX-99.1
SAVA
Cassava Sciences Inc
7 Feb 24
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
9:20am
are communicating top-line data so that stakeholders may have timely access to a summary of the open-label study findings prior to us receiving the final dataset
424B2
SAVA
Cassava Sciences Inc
3 Jan 24
Prospectus for primary offering
4:22pm
plans. We regularly evaluate opportunities to access capital markets, taking into account our capital needs, financial condition, strategic plans … in a prospectus supplement.
Such electronic system may allow bidders to directly participate, through electronic access to an auction site, by submitting
8-K
EX-99.1
77h1d
5 Jul 23
Other Events
9:25am
8-K
EX-1.1
9u01u tew450
1 May 23
Entry into a Material Definitive Agreement
5:26pm
424B5
4hga4
1 May 23
Prospectus supplement for primary offering
5:26pm
S-3ASR
8lwwu8z
1 May 23
Automatic shelf registration
4:01pm
8-K
EX-10.1
65ohcir2o8kr 0zug
22 Nov 22
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
12:49pm
424B5
y2dl879lecrdbzkfsf
21 Nov 22
Prospectus supplement for primary offering
8:00am
8-K
uxmrnucyx4 0a6
23 Sep 22
Regulation FD Disclosure
9:05am
8-K
EX-99.1
323lxxozs7f9
3 Aug 22
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study
9:25am
424B5
mae wwa9kaqvadyzpg
29 Jul 22
Prospectus supplement for primary offering
4:15pm